Neoadjuvant chemotherapy improves outcomes in resectable pancreatic adenocarcinoma.

ABSTRACT:

Background/objectives

Systemic chemotherapy is recommended for all stages of pancreatic ductal adenocarcinoma (PDAC), with a recent shift towards neoadjuvant chemotherapy (NAC) for resectable PDAC. The objective of this study was to compare outcomes of NAC versus AC for early stage resectable PDAC in the NCDB. Methods: Patients aged 18 or older with stage I or II PDAC in the National Cancer Database (NCDB) from 2010 to 2017 were identified. Logistic regression evaluated oncologic outcomes. Kaplan-Meier method followed by Cox proportional-hazards regression with inverse probability of treatment weighting (IPTW) using propensity score matching was used to compare overall survival (OS).

Results

NAC led to a 13% risk reduction of a positive resection margin (OR:0.87; 95%CI 0.78-

SUBMITTER: Christopher W 

PROVIDER: S-EPMC11749821 | biostudies-literature | 2022 Dec

REPOSITORIES: biostudies-literature